


AMENDMENTS TO THE CLAIMS

1. (Original) A diaryl methyl derivative of Formula I



(I)

or a pharmaceutically-acceptable addition salt thereof, wherein,

Ar¹ and Ar², independently of one another, represent an aromatic carbocyclic or heterocyclic monocyclic group, which aromatic carbocyclic or heterocyclic monocyclic group is optionally substituted one or more times with substituents selected from the group consisting of alkyl, alkoxy, halo, haloalkyl, haloalkoxy, cyano and nitro;

L is absent (i.e. represents a single bond) or represents a linker selected from the group consisting of -CH₂-, -CH₂CH₂-, -CH(CH₃)-, -CH₂CH₂CH₂-, -CH₂CH(CH₃)-, -S-, -S-CH₂-, -S-CH₂CH₂-, -S-CH(CH₃)-, -S-CH₂CH₂CH₂-, -S-CH₂CH(CH₃)-, -NH-, -NH-CH₂-, -NH-CH₂CH₂-, -NH-CH(CH₃)-, -NH-CH₂CH₂CH₂- and -NH-CH₂CH(CH₃)-; and

A and B, independently of one another, represent

-CN; -COOR', -CONR'R'', -C(=NOR')R'' or -C(=NOR')NR''R''', wherein R', R'' and R''', independently of one another, represent hydrogen or alkyl;

pyridinyl, phenyl, -SO₂-phenyl or -O-SO₂-phenyl, which phenyl group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, alkoxy, halo, haloalkyl, haloalkoxy, cyano and nitro; or

A represents -CN; -COOR', -CONR'R'', -C(=NOR')R'' or -C(=NOR')NR''R''', wherein R', R'' and R''', independently of one another, represent hydrogen or alkyl; pyridinyl,

-SO₂-phenyl or -O-SO₂-phenyl, which phenyl group may optionally be substituted with alkyl, alkoxy, halo, haloalkyl, haloalkoxy, cyano and nitro; and

B represents -CN, -COOR' or -CONR'R'', wherein R' and R'', independently of one another, represent hydrogen or alkyl; a phenyl group, which phenyl group is optionally substituted one or two times with alkyl, alkoxy, halo, haloalkyl, haloalkoxy, cyano and/or nitro; or a pyridinyl group, which pyridinyl group is optionally substituted one or two times with alkyl, alkoxy, halo, haloalkyl, haloalkoxy, cyano and/or nitro.

2. (Original) The compound of claim 1, wherein

L represents a linker selected from the group consisting of -CH₂-, -CH₂CH₂-, -CH₂CH₂CH₂-, -CH₂CH(CH₃)-, -S-, -S-CH₂- and -S-CH(CH₃)-.

3. (Currently Amended) The compound of claim 1 ~~either one of claims 1-2~~, wherein

A and B, independently of one another, represent

-CN; -COOR', -CONR'R'', -C(=NOR')R'' or -C(=NOR')NR''R''', wherein R', R'' and R''', independently of one another, represent hydrogen or alkyl;

pyridinyl, phenyl, -SO₂-phenyl or -O-SO₂-phenyl, which phenyl group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, alkoxy, halo, haloalkyl, haloalkoxy, cyano and nitro.

4. (Currently Amended) The compound of claim 1 ~~either one of claims 1-2~~, wherein

A represents -CN; -COOR', -CONR'R'', -C(=NOR')R'' or -C(=NOR')NR''R''', wherein R', R'' and R''', independently of one another, represent hydrogen or alkyl; pyridinyl,

-SO₂-phenyl or -O-SO₂-phenyl, which phenyl group may optionally be substituted with alkyl, alkoxy, halo, haloalkyl, haloalkoxy, cyano and nitro; and

B represents -CN, -COOR' or -CONR'R'', wherein R' and R'', independently of one another, represent hydrogen or alkyl; a phenyl group, which phenyl group is optionally substituted one or two times with alkyl, alkoxy, halo, haloalkyl, haloalkoxy, cyano and/or nitro; or a pyridinyl group, which pyridinyl group is optionally substituted one or two times with alkyl, alkoxy, halo, haloalkyl, haloalkoxy, cyano and/or nitro.

5. (Original) The compound of claim 4, wherein

A represents -COOH, -COOCH₃, -COOCH₂CH₃, -CONH₂, -C(=NOH)NH₂, pyridinyl or -O-SO₂-phenyl, which phenyl group is substituted with alkyl or halo, haloalkyl, cyano or nitro; and

B represents -CONH₂, -CN, or a phenyl group substituted with fluoro.

6. (Original) The compound of claim 5, wherein

A represents -COOH, -COOCH₃, -COOCH₂CH₃, -CONH₂, -C(=NOH)NH₂; and

B represents -CONH₂, -CN.

7. (Original) The compound of claim 5, wherein

A represents pyridin-2-yl, pyridin-3-yl, pyridin-4-yl or -O-SO₂-phenyl, which phenyl group is substituted with methyl or ethyl; and

B represents -CN.

8. (Currently Amended) The compound of claim 1~~any one of claims 1-7~~, wherein

Ar¹ and Ar², independently of one another, represent

a phenyl group, which phenyl group is substituted one or two times with alkyl, alkoxy, halo, haloalkyl, cyano and/or nitro; or

a pyridinyl group, which pyridinyl group is optionally substituted one or two times with alkyl, alkoxy, halo, haloalkyl, cyano and/or nitro.

9. (Original) The compound of claim 8, wherein

both of Ar¹ and Ar² represent a phenyl group, which phenyl groups, independently of one another, are substituted one or two times with halo, haloalkyl, cyano and/or nitro; or

both of Ar¹ and Ar² represent a pyridinyl group, which pyridinyl groups, independently of one another, are optionally substituted one or two times with halo, haloalkyl, cyano and/or nitro.

10. (Original) The compound of claim 9, wherein

both of Ar¹ and Ar² represent a halo-substituted phenyl group.

11. (Currently Amended) The compound of claim 8~~any one of claims 8-10~~, wherein

L represents -CH₂-, -CH₂CH₂-, -CH₂CH₂CH₂-, -CH₂CH(CH₃)-, -S-, -S-CH₂- or -S-CH(CH₃)-.

12. (Currently Amended) The compound of claim 8~~any one of claims 8-10~~, wherein

A represents -COOH, -COOCH₃, -COOCH₂CH₃, -CONH₂, -C(=NOH)NH₂; and

B represents -CONH₂, -CN.

13. (Original) The compound of claim 10, which is

2,2-Bis-(4-fluoro-phenyl)-succinamide;

3-Cyano-3,3-bis-(4-fluoro-phenyl)-propionic acid;

p-Toluenesulfonic acid 2-cyano-2,2-bis-(4-fluoro-phenyl)-ethyl ester;

Ethyl 4-cyano-4,4-bis-(4-fluoro-phenyl) butyrate; or

2-[(2-Fluoro-phenyl)-bis-(4-fluoro-phenyl)-methanesulfanyl]-*N*-hydroxy acetamidine;

or a pharmaceutically-acceptable addition salt thereof.

14. (Original) The compound of claim 9, wherein both of Ar¹ and Ar² represent a phenyl group, which phenyl groups, independently of one another, are substituted one or two times with halo, haloalkyl, cyano and/or nitro.

15. (Original) The compound of claim 14, wherein

L represents -CH₂-, -CH₂CH₂-, -CH₂CH₂CH₂-, -CH₂CH(CH₃)-, -S-, -S-CH₂- or -S-CH(CH₃)-.

16. (Currently Amended) The compound of claim 14 ~~either one of claims 14-15,~~
wherein

A represents pyridinyl, in particular pyridin-2-yl, pyridin-3-yl or pyridin-4-yl; and

B represents -CONH₂, -CN.

17. (Original) The compound of claim 14, which is

2-(4-Fluoro-phenyl)-2-(4-nitro-3-trifluoromethyl-phenyl)-3-pyridin-2-yl-propionitrile;

or a pharmaceutically-acceptable addition salt thereof.

18. (Original) The compound of claim 9, wherein both of Ar¹ and Ar² represent a pyridinyl, in particular a pyridin-2-yl, a pyridin-3-yl or a pyridin-4-yl group.

19. (Original) The compound of claim 18, wherein

L represents -CH₂-, -CH₂CH₂-, -CH₂CH₂CH₂-, -CH₂CH(CH₃)-, -S-, -S-CH₂- or -S-CH(CH₃)-.

20. (Currently Amended) The compound of claim 18~~either one of claims 18-19~~,
wherein

A represents -COOH, -COOCH₃, -COOCH₂CH₃, -CONH₂, -C(=NOH)NH₂; and

B represents -CONH₂, -CN.

21. (Original) The compound of claim 18, which is

Methyl 4-cyano-4,4-bis-(pyridin-2-yl) butyrate; or

Methyl 4-cyano-2-methyl-4,4-bis-(pyridin-2-yl) butyrate;

or a pharmaceutically-acceptable addition salt thereof.

22. (Currently Amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1~~any one of claims 1-21~~, or a pharmaceutically-acceptable addition salt thereof.

23. (Currently Amended) A method for of treatment, prevention or alleviation of a disease or a disorder or a condition responsive to modulation of SK_{Ca} and/or IK_{Ca} channels, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a compound of claim 1.

~~Use of a compound of any one of claims 1-21, or a pharmaceutically acceptable addition salt thereof, for the manufacture of a medicament for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to modulation of SK_{Ca} and/or IK_{Ca} channels.~~

24. (Currently Amended) The method~~use~~ according to claim 23, which disease, disorder or condition relates to reduction or inhibition of undesired immune-regulatory actions, including graft vs. host syndrome, transplant rejection, or transplant rejection.

25. (Currently Amended) The method~~use~~ according to claim 23, for the manufacture of a pharmaceutical composition, which further comprises a pharmaceutically effective amount of a conventional immune suppressing agent.

26. (Currently Amended) The method~~use~~ according to claim 25, wherein the conventional immune-suppressing agent is Amphotericin, Busulphan, Co-trimoxazole,

Chlorambucil, colony stimulating factors, corticosteroids, Cyclophosphamide, Fluconazole, folinic acid, Ganciclovir, antilymphocyte immunoglobulins, normal immunoglobulins, Methotrexate, Methylprednisolone, Octreotide, Oxpentifylline, Tacrolimus (FK506), Thalidomide, Zolimomabaritox, or the calcineurin inhibitors (protein phosphatase 2B inhibitors), in particular Cyclosporin.

Claim 27 (CANCELLED)